Prognostic relevance of ATM protein in uveal melanoma and its association with clinicopathological factors. 2019

Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
Department of Ocular Pathology, Dr. R.P. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.

OBJECTIVE Uveal melanoma (UM) is an intraocular malignancy commonly arising from choroid which can cause visual loss or metastasis. Ataxia-telangiectasia mutated (ATM) protein is an activator of DNA damage response and its role in uveal melanoma (UM) is still unexplored. Therefore, the study aims to detect the expression and localization of ATM protein and its association with clinicopathological parameters METHODS: Expression of nuclear ATM (nATM) was investigated on 69 formalin fixed paraffin embedded choroidal melanoma samples by immunohistochemistry and validated by western blotting. Results were then correlated with clinical and histopathological parameters. Prognostic significance was determined by the Kaplan-Meier analysis and the multivariate analysis by Cox's hazard proportional method. RESULTS Loss of nATM was observed in 65% of cases, which was statistically significant with the reduced disease-free survival (p = 0.042). This loss was more frequently found in cases with high-risk histopathological factors like epithelioid cell type, tumor infiltrating lymphocytes and high pigmentation which might help in the progression of melanoma. On multivariate analysis, extraocular spread and loss of nATM were found to be independent prognostic factors (p < 0.05). CONCLUSIONS Our data suggest that loss of nATM protein might serve as a poor prognostic marker in the pathogenesis of uveal melanoma which may lead to increased risk of metastasis.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
June 2001, Melanoma research,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
January 2015, Vestnik oftalmologii,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
December 2019, Experimental and molecular pathology,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
April 2024, JPMA. The Journal of the Pakistan Medical Association,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
January 2020, Therapeutic advances in medical oncology,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
January 2011, Oncology,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
February 2012, Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
December 2014, The British journal of ophthalmology,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
October 1990, Cancer,
Jayanti Jha, and Mithalesh Kumar Singh, and Lata Singh, and Neelam Pushker, and Mandeep Singh Bajaj, and Seema Sen, and Seema Kashyap
September 2022, Genes,
Copied contents to your clipboard!